MILAN ― Numerous unresolved questions surround progressive pulmonary fibrosis (PPF) treatment, according to Elisabeth Bendstrup, MD, PhD, a researcher and clinical professor in the Department of ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted breakthrough therapy designation to an oral lysophosphatidic acid receptor 1 antagonist that ...

In a recent study published in The Lancet Respiratory Medicine, a team of researchers compared the efficacy of the controlled release of low-dose morphine as an antitussive treatment against that of a ...

Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced positive results of the COMPANION study ...

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...